MRC ENTERPRISE STUDENTSHIP PROGRAMME 2022 - Discrete choice experiment (DCE) to understand variation in uptake of respiratory disease vaccination in working age adults
MRC ENTERPRISE STUDENTSHIP PROGRAMME 2022 (INDUSTRIAL CASE AWARDS)
Eight industrial CASE (iCASE) studentships are available for doctoral study at Oxford, to start in October 2022. Each iCASE studentship is fully-funded for four years with a stipend of the UKRI stipend level + £2,500 p.a., all course fees paid, plus a research training support grant. Applications must be received by 12 noon (UK time) Friday 3 December 2021. Details on how to apply can be found below.
Designed to nurture the academic entrepreneurs of the future, the Enterprise studentship programme offers a stimulating educational experience as part of the Oxford-MRC DTP cohort, with the additional benefit of working closely with an industrial partner. This will provide entrepreneurial training opportunities and an insight into how commercial science is conducted alongside a superb academic base within the University. Students will work for at least 3 months in the associated company.
Full details of scheme can be found here: https://www.medsci.ox.ac.uk/study/graduateschool/mrcdtp/iCASE-2022
DISCRETE CHOICE EXPERIMENT (DCE) TO UNDERSTAND VARIATION IN UPTAKE OF RESPIRATORY DISEASE VACCINATION IN WORKING AGE ADULTS
Lead supervisor: Professor Stavros Petrou
In contrast to older adults (≥65years), working age adults (18-64years) have much lower uptake of respiratory disease vaccines. Whereas influenza vaccination coverage in people over 65 years is always over 70% (Lusignan, 2016), it has been much lower in younger adults; for example, those >50years have had around 55% uptake with even lower rates seen in adult risk groups. Similarly, only 32% of eligible adults, in risk groups, are receiving a pneumococcal polysaccharide vaccine (PPV) (Matthews, 2020). Although much higher rates of COVID-19 vaccination have been achieved (as of 18th July, 93.9% of adults over 50 had received two doses of a COVID-19 vaccination), there are similar age gradients in uptake with younger adults and pregnant women with lower uptake. Encouraging uptake across a range of respiratory diseases, particularly in risk groups, could confer sizeable public health gains because rates in these risk groups are low. Understanding choice behaviour around vaccination is critical to this goal.
A discrete choice experiment (DCE) to understand what influences vaccine uptake in eligible, working age adults (aged 16 to 65 years). We will focus on vaccines for: pneumococcal infections, influenza and COVID-19.
Discrete Choice Experiments (DCEs) are an established method in health sciences (Genie, 2020), for understanding the behaviours of vaccine-eligible adults toward vaccine uptake and characteristics that can influence their vaccination decisions.
The design of the DCE will be based on systematic reviews, consultation with clinicians, and secondary data. Recent work has used data from DCEs and extended it in two important ways that will enhance the validity of the findings: (i) in combination with data from the real world to enhance external validity (Buckell and Hess, 2019); (ii) incorporating psychology, e.g. information inattention, into mathematical models of behaviour to better understand choices (Erdem et al., 2014; Buckell and Sindelar, 2019).
Sampling both from the general population and among at-risk groups will enable findings that are applicable at the population level and that respond to specific public health priorities.
(1) Systematic review of respiratory virus vaccine uptake in working age adults;
(2) Study the attitudes/psychology of these three vaccines before and after the introduction of the COVID-19 vaccine and analyse behaviors among vulnerable groups;
(3) Pilot then main experimental work running DCEs through the EMIS Access portal with volunteer patients; sampling from the general population and specific risk groups.
(4) Use DCE data in behavioural models, combined with patient record data, to forecast how features of vaccines (e.g. pharmacy or surgery administration) impact on uptake, and so how GPs can encourage uptake; and
(5) Study the economic impact of respiratory disease vaccination uptake on GP practices.
COVID-19 and other respiratory diseases are key priorities. Understanding vaccination behaviours across a range of respiratory diseases would enable more effective prevention and management. This project will contribute to MRC methodological priorities by combining and advancing the health economic and behavioural science/psychology methodologies, developing generalizable methods for use across MRC research areas.
Benefits for EMIS & academics:
EMIS would strengthen our relationships with practices and patients. EMIS is looking to expand its work with the research community; the proposed research would provide an appropriate case study.
Commercial partner: EMIS Group PLC, Leeds
This project must be undertaken on the programme DPhil in Primary Health Care